HIV/AIDS Clinical Trials

Showing 181-200 of 3,256 trials

Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV

NCT07054931

There is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma. A new therapy, broadly neutralising antibodies, (bNAbs), may work as well as ART and may last longer - one dose can last six months. bNAbs appear to first target HIV viruses, then drive a protective immune response conferring long-term control, called the vaccinal effect. AbVax is a clinical trial to understand this effect and how to enhance it to give the strongest possible long-term protection for people living with HIV (PWH). The investigators are studying whether a combination of vaccines that attack HIV, a short period of treatment interruption induced viraemia (TIIV - stopping ART for a few weeks to allow a small amount of virus to return to the bloodstream) and bNABs will produce the most sustained immune protection.

HIV

University of Oxford48 participantsStarted Sep 2025

London, United Kingdom • London, United Kingdom • Oxford, United Kingdom

COMPLETEDNA

CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.

NCT04814654

While HIV prevalence among Men Seeking Men (MSM) in India is 10-15 times higher than in the general population (4.3% vs 0.3%), current interventions for Indian MSM have limited reach. In order to reduce the burden of HIV in MSM, innovative, far-reaching prevention and treatment strategies are needed. Guided by the increase access to internet-based social and mobile technologies (SMT) (e.g., SMS, WhatsApp, dating apps) globally and in India, this is a 3-arm parallel, pragmatic randomized controlled trial of community-developed, theory based behavioral intervention (CHALO! 2.0) delivered via WhatsApp (secure SMS application) compared to an Attention-Matched Control, or a Digital Coupon for free HIV testing only control conditions. The primary outcomes are HIV-testing at 6 months (3 months after the end of the intervention) and linkage-to-preventive care (counseling or pre-exposure prophylaxis) at 12 months. The secondary outcomes are the frequency of HIV-testing by 18 months.

Hiv

Albert Einstein College of Medicine1,004 participantsStarted Apr 2022

Mumbai, Maharashtra, India

Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV

CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.

Related Searches

Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

The Unlocking PrEP Study: Integration of Peer Health Navigation Into Comprehensive Re-entry Services

CAbotégravir LENacapavir DUal Long Acting

Intervention for Virologic Suppression in Youth

Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV

Suubi+Adherence4Youth

The SMART ART Study

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.

Palliative Care Educator

Botswana Smoking and Abstinence Reinforcement Trial

ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV

DSD Models at South Africa Sentinel Sites

DSD Models at Zambia Sentinel Sites (SENTINEL 2)